NCT03046953View on ClinicalTrials.gov

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

July 31, 2020

Study Completion Date

July 27, 2021

Conditions
T-Cell Lymphoma RelapsedT-Cell Lymphoma Refractory
Interventions
DRUG

Avelumab

anti-PDL1 antibody

Trial Locations (1)

NW1 2BU

University College London Hospital, London

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Bloodwise

OTHER

collaborator

Pfizer

INDUSTRY

lead

University of Birmingham

OTHER

NCT03046953 - Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma | Biotech Hunter | Biotech Hunter